Celltrion, Inc.
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
068270 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068270008
- LEI:
- Country:
- South Korea
- Address:
- 인천광역시 연수구 아카데미로 23, 인천광역시
- Website:
- https://www.celltrion.com/
- Sector:
- Manufacturing
Description
Celltrion, Inc. is a biopharmaceutical company that provides integrated solutions across the entire value chain, from research and development to clinical trials, regulatory affairs, and large-scale manufacturing. The company specializes in developing and producing innovative therapeutics, including biosimilars and novel biopharmaceuticals. Its portfolio primarily targets autoimmune diseases and oncology. Celltrion is recognized for launching the world's first monoclonal antibody biosimilar. A key product is ZYMFENTRA® (infliximab-dyyb), a subcutaneous formulation for the maintenance treatment of moderately-to-severely active Crohn's disease and ulcerative colitis. The company also develops and manufactures chemical pharmaceuticals.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-12-23 00:00 |
투자판단관련주요경영사항 (앱토즈마주(CTP47, 악템라주 바이오시밀러) 한국(MFDS) 품목허가 획득)
|
Korean | 8.1 KB | ||
| 2024-12-18 00:00 |
투자판단관련주요경영사항 (스테키마(CTP43, 스텔라라 바이오시밀러) 미국식품의약국(FDA) 최종 판매 허가 획득)
|
Korean | 9.3 KB | ||
| 2024-12-18 00:00 |
자기주식취득결과보고서
|
Korean | 29.4 KB | ||
| 2024-12-17 00:00 |
타법인주식및출자증권취득결정(자율공시)
|
Korean | 14.6 KB | ||
| 2024-12-17 00:00 |
투자판단관련주요경영사항 (CTP13 SC(짐펜트라) 유럽 임상 3상 시험계획 승인(Part1&2) (류마티스 관절염 환…
|
Korean | 11.6 KB | ||
| 2024-12-16 00:00 |
투자판단관련주요경영사항 (CTP41(프롤리아&엑스지바 바이오시밀러) 유럽의약품청(EMA) 산하 약물사용자문위원회(CHM…
|
Korean | 10.2 KB | ||
| 2024-12-16 00:00 |
투자판단관련주요경영사항 (CTP42(아일리아 바이오시밀러) 유럽의약품청(EMA) 산하 약물사용자문위원회(CHMP) 판매…
|
Korean | 9.3 KB | ||
| 2024-12-16 00:00 |
투자판단관련주요경영사항 (CTP47(로악템라 바이오시밀러) 유럽의약품청(EMA) 산하 약물사용자문위원회(CHMP) 판매…
|
Korean | 9.6 KB | ||
| 2024-12-13 00:00 |
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.8 KB | ||
| 2024-12-13 00:00 |
현금ㆍ현물배당결정
|
Korean | 9.7 KB | ||
| 2024-12-13 00:00 |
주식배당결정
|
Korean | 7.5 KB | ||
| 2024-12-13 00:00 |
투자판단관련주요경영사항 (CTP51(키트루다 바이오시밀러) 유럽 임상 3상 시험계획 승인(Part1&2))
|
Korean | 11.5 KB | ||
| 2024-12-11 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.9 KB | ||
| 2024-12-06 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 21.4 KB | ||
| 2024-12-04 00:00 |
주식소각결정
|
Korean | 9.0 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celltrion, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
